## Background: Erythrodermic cutaneous t-cell lymphomas (ctcl) including sΓ©zary syndrome have been successfully treated with daily administration of chlorambucil and prednisone (winkelmann regimen). ## Objectives: Our purpose was to determine the efficacy and safety of a low-dose pulse chemothera
Leucoderma associated with flares of erythrodermic cutaneous T-cell lymphomas: four cases
β Scribed by A. Bouloc; F. Grange; M.H. Delfau-Larue; M.T. Dieng; M.C. Tortel; M.F. Avril; J. Revuz; M. Bagot; J. Wechsler; For The French Study Group Of Cutaneous Lymphomas
- Publisher
- John Wiley and Sons
- Year
- 2000
- Tongue
- English
- Weight
- 643 KB
- Volume
- 143
- Category
- Article
- ISSN
- 0007-0963
No coin nor oath required. For personal study only.
β¦ Synopsis
We describe four patients with erythrodermic cutaneous T-cell lymphomas (two with erythrodermic mycosis fungoides, and two with SΓ©zary syndrome) who presented with extensive hypopigmented lesions that occurred during flares of their cutaneous disease. These cases must be distinguished from previously described hypopigmented mycosis fungoides where hypopigmented lesions were the sole manifestation of the lymphoma. In two cases a biopsy was performed on hypopigmented skin, showing an infiltrate of atypical lymphocytes with epidermotropism and absence of melanocytes, as in vitiligo. It is suggested that the hypopigmentation could be due to the cytotoxicity of tumour or reactional lymphocytes directed against melanocytes.
π SIMILAR VOLUMES
Epstein-Barr virus (EBV)-associated T/natural killer (NK) cell lymphoma mainly shows nasal lesions, and has recently been shown to be associated with cutaneous T-cell lymphoma (CTCL). The detailed features of CTCL nasal metastasis have yet to be elucidated. We report clinicopathological findings for
## Abstract CD8+ cutaneous Tβcell lymphoma (CTCL) is a relatively rare subset of the nonβHodgkins lymphomas. Bexarotene has been FDAβapproved for the treatment of CTCL, but previous studies have been conducted on CD4+ CTL and there have been no reports about its use in CD8+ CTCL. Herein, we report